Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,885 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06877650RecruitingPhase 1/Phase 2
Study of JMT108 for advanced solid tumors
This trial tests a new drug called JMT108 for people with advanced solid tumors that haven't responded to standard treatments. It aims to find out if the drug is safe and how well it works against cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06882135RecruitingPhase 1
Testing an experimental drug for advanced solid tumors
This trial studies a new drug called HW071021 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can help shrink or control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06341335RecruitingPhase 3
AK104 and AK109 plus paclitaxel for advanced stomach cancer
This trial tests a combination of two experimental immunotherapies (AK104 and AK109) with a standard chemo drug (paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has grown after initial treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer better than chemo alone.
BeijingAges 18–75 - NCT06866938RecruitingPhase 2
Second course of PSMA-targeted radiation for prostate cancer
This study tests giving the targeted radiation drug [177Lu]Lu-PSMA again to men whose prostate cancer has started growing after an earlier course of the same treatment. It aims to see if a second round can control the cancer again.
BordeauxAges 18 years+ - NCT05416775RecruitingPhase 1/Phase 2
Test drug SHR-8068 for advanced lung cancer
This trial tests SHR-8068 in people with advanced non-small cell lung cancer (NSCLC). It may help by controlling cancer after standard treatments have not worked, and it’s designed to find the right way to give the drug.
Hefei, AnhuiAges 18–75 - NCT06752044Recruiting
Vaccine, immunotherapy, and radiation for advanced lung cancer
This trial tests a combination of a personalized vaccine (made from your tumor's unique markers), a drug that boosts your immune system (PD-1 inhibitor), and targeted radiation for people with advanced lung cancer that has progressed after initial treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Nanchang, JiangxiAges 18–70 - NCT06841679RecruitingPhase 2/Phase 3
Testing utidelone plus chemo for untreated stomach cancer
This trial tests a new capsule (utidelone) combined with standard chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. It aims to see if this combination works better than current options.
Hialeah, FloridaAges 18 years+ - NCT06825494RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hefei, AnhuiAges 18 years+ - NCT06830850RecruitingPhase 1
Testing a new drug for metastatic prostate cancer
This trial tests a new drug, HRS-5041, for men whose prostate cancer has spread and stopped responding to hormone therapy. The goal is to see if the drug is safe and can help control the cancer.
Sydney, New South WalesAges 18 years+ - NCT06822998RecruitingEarly Phase 1
HF50 for HER-2 positive and low-expression advanced tumors
This trial tests a new drug, HF50, in people with advanced solid tumors that are HER-2 positive or have low HER-2 levels. It may be an option if standard treatments have stopped working or are not tolerated.
Chengdu, SichuanAges 18–75 - NCT06440902RecruitingPhase 2
New treatments for RAS-changed colorectal cancer using blood tests
This study tests new treatment plans for people with metastatic colorectal cancer whose tumors originally had a RAS mutation but later show no RAS mutation in blood tests. The goal is to see if these treatment changes can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06353854Recruiting
Study of biomarkers in MSI-high colorectal cancer patients on immunotherapy
This trial is studying people with a specific type of advanced colorectal cancer (MSI-high/dMMR) who are starting immunotherapy with pembrolizumab. The goal is to find out which markers in the tumor might predict whether the treatment works well.
BayonneAges 18 years+ - NCT06241456RecruitingPhase 1
Experimental CAR-T cells targeting HER2 for advanced solid tumors
This trial tests an experimental 'off-the-shelf' CAR-T cell therapy (called FT825/ONO-8250) that targets a protein called HER2 found on some solid tumors. It may be given alone or with other antibodies to help fight advanced cancer that has not responded to standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06084286RecruitingPhase 1
CAR-T therapy targeting CLDN18.2 and PD-L1 for advanced solid tumors
This trial tests a new type of cell therapy (CAR-T) that targets two proteins, CLDN18.2 and PD-L1, found on some cancer cells. It is for people with advanced solid tumors like stomach, esophageal, or pancreatic cancer that have stopped responding to standard treatments.
Chengdu, SichuanAges 18–75 - NCT05613738Recruiting
Test drug for advanced prostate cancer with high PSMA scans
This trial studies whether a PSMA-targeted treatment using 177Lu can help men with prostate cancer that has spread and is growing despite hormone treatment. It may help if your scan shows high PSMA in the tumor and your blood counts and organ function are adequate.
Beijing, Beijing MunicipalityAges 18–80 - NCT07639450RecruitingPhase 1/Phase 2
N-3C01 Cancer Treatment Study for Advanced Solid Tumors
This trial tests a new drug called N-3C01, alone or combined with immune-boosting medications, in patients whose advanced cancer has stopped responding to standard treatments. The goal is to see if this approach can slow or shrink tumors that have become resistant to other therapies.
Saint Leonards, New South WalesAges 18–75 - NCT07405346Enrolling by invitation
Organoid-guided treatment for advanced leiomyosarcoma
This trial uses your tumor's lab-grown organoids to find the most effective personalized treatment for advanced leiomyosarcoma. It aims to match you with a drug that targets your specific cancer.
Wuhan, HubeiAges 18–75 - NCT07634380RecruitingPhase 1
Sitagliptin Plus Pembrolizumab for Advanced Kidney or Skin Cancer
This study tests whether adding sitagliptin (a diabetes medication) to pembrolizumab (an immunotherapy) can help patients with advanced kidney cancer or melanoma whose cancer stopped responding to previous immunotherapy treatments. The goal is to see if this combination can shrink tumors and improve survival.
Iowa City, IowaAges 18–99 - NCT06710158RecruitingPhase 1
SC-102 for advanced solid tumors
This trial tests a new drug called SC-102 in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if SC-102 is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06773091RecruitingPhase 1
NK cell therapy for advanced solid tumors
This trial tests an investigational NK cell therapy (NK042) for people with advanced solid tumors that have not responded to standard treatments. The aim is to see if this cellular therapy is safe and potentially effective.
BeijingAges 18–70 - NCT06772415RecruitingPhase 1
Study of GenSci122 for advanced solid tumors
This trial tests an experimental pill called GenSci122 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT05613413RecruitingPhase 2
Maintenance cabozantinib plus pembrolizumab after lung cancer control
This trial tests whether continuing treatment with cabozantinib plus pembrolizumab after your metastatic squamous lung cancer responds (or is stable) can help people live longer and stay in control. It may be an option if your cancer has already shown it can respond to initial (first-line) treatment.
Chicago, IllinoisAges 18 years+ - NCT07380334RecruitingPhase 1
Studying SHR-1049 for advanced solid tumors
This study is testing a new drug called SHR-1049 for people with advanced solid tumors (cancers that have spread). It looks at safety, how the drug moves through the body, and whether it helps shrink tumors. You may be eligible if you have tried standard treatment without success or no standard treatment exists.
Hangzhou, ZhejiangAges 18–75 - NCT07230977RecruitingPhase 1
GenSci139 for advanced solid tumors
This Phase 1 trial tests an experimental drug called GenSci139 for people with advanced solid tumors (cancers that have spread) that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
Jinan, ShandongAges 18 years+
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,885 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.